Introduction {#S0001}
============

Recent studies suggest that serum level of 25-hydroxyvitamin D \[25(OH)D\] lower than 20 ng/mL or a vitamin D-deficient status, is associated with increased risk of cardiovascular diseases (CVD),[@CIT0001] including hypertension,[@CIT0002] heart failure,[@CIT0003] and ischemic heart disease[@CIT0004]--[@CIT0006]. Several reports also indicated that severe vitamin D deficiency defined as 25(OH)D \<10 ng/mL is a predictor for sudden cardiac arrest in individuals with pre-existing CVD.[@CIT0007] Vitamin D is believed to impact CVD through various mechanisms including impaired glucose and lipid metabolism pathways.[@CIT0008] Many of these pathways are relevant to insulin resistance as well, given that insulin resistance is a risk factor for dyslipidemia and low levels of serum 25(OH)D.[@CIT0009]

Although the association between 25(OH)D and serum lipid profile has been reported in numerous studies,[@CIT0010],[@CIT0011] this association may vary by insulin resistance status. Epidemiological studies suggest an inverse association between 25(OH)D and serum lipid profile[@CIT0012] although it is highly controversial which lipid may be affected by increased serum 25(OH)D levels. Randomized clinical trials (RCTs) have yielded conflicting results.[@CIT0013],[@CIT0014] Of note, these studies were limited by confounding effects of vitamin D with added calcium supplementation; and study designs that were not precisely aimed at vitamin D-deficient status or did not use a sufficient dose of vitamin D to achieve optimal serum level for 25(OH)D (\>30ng/mL).[@CIT0015]

There are evidence suggesting a correlation between low-grade inflammation and insulin-resistant states, as some studies have revealed a clear association between the chronic activation of pro-inflammatory pathways such as nuclear-κB (NF- κB) and decreased insulin sensitivity.[@CIT0016] Elevated levels of tumor necrosis factor-α (TNF), interleukin-6 (IL-6) and interleukin (IL-8) have all been reported in insulin-resistant states.[@CIT0017] Chronic inflammation in these individuals plays an important role in the development of atherosclerosis leading to increased CVD risk.[@CIT0018] In addition, endothelial dysfunction may be associated with the pathogenesis of insulin resistance syndrome. Plasma thrombomodulin (TM) levels also reflect endothelial damage in the state of insulin resistance.[@CIT0019]

In the absence of definitive evidence, there is a need to further investigate how changes in serum 25(OH)D level are related to changes in atherogenic lipid levels and circulatory inflammatory markers in insulin-resistant individuals who are at higher risk of cardiovascular events.[@CIT0020] Therefore, in this cross-sectional approach, we studied the association between serum 25(OH)D level and the lipid profile as well as the circulatory inflammatory markers in a large population derived from the Dubai and Northern Emirates of the United Arab Emirates (UAE).

Methods {#S0002}
=======

Ethical Considerations {#S0002-S2001}
----------------------

Ethical approval for the United Arab Emirates National Diabetes and Lifestyle (UAEDIAB) study was obtained from the University of Sharjah Research Ethics Committee and UAE Ministry of Health (Al-Qassimi Hospital) Research Ethics Committee. Written informed consent was obtained from all study participants.

Study Population {#S0002-S2002}
----------------

The UAEDIAB study had 5020 individuals across the UAE.[@CIT0021],[@CIT0022] We selected the data from 4114 adult individuals that included simultaneous serum 25(OH)D level, lipid panels, and fasting serum insulin tests during 2013 for analysis ([Figure 1](#F0001){ref-type="fig"}). These individuals met the following inclusion criteria: were 18 to 80 years of age and had simultaneous 25(OH)D, lipid panel, and fasting serum insulin tests inclusive. The exclusion criteria were pregnant and those who were on lipid-lowering medications.Figure 1Flow diagram of UAEDIAB cohort and analytic sample.

Serum 25(OH)D Concentration {#S0002-S2003}
---------------------------

Serum 25(OH)D level was measured using chemiluminescent immunoassay (DiaSorin, LIAISON 25^®^Vitamin D TOTAL Assay), according to the manufacturer's instructions. The coefficient of variation for the instrument was between 10% and 15%, and the sensitivity for the assay was 4 ng/mL.[@CIT0023] We stratified 25(OH)D results into consensus clinical strata:[@CIT0024] deficient (\<20 ng/mL; n=796), sufficient (20--50 ng/mL; n=2502), and high serum 25(OH)D concentration (\>50 ng/mL; n=461). For multiple regression analysis, vitamin D status was reported as sufficient (20--50 ng/mL) or deficient (\<20 ng/mL).

Lipid Panels {#S0002-S2004}
------------

The lipid panel results including total cholesterol (TC), low-density lipoprotein-cholesterol (LDL)-C, triglycerides (TG), and high-density lipoprotein-cholesterol (HDL-C) were stratified into high or low levels of dyslipidemia based on consensus clinical strata:[@CIT0025],[@CIT0026] high TC (\> 6.2 mmol/L; n=516), high LDL-C (\>2.59 mmol/L; n=3130), high TG (\>2.3 mmol/L; n=708), and low HDL-C (\<1.55 mmol/L; n=3501) dyslipidemia.[@CIT0027] Total cholesterol and triglyceride were measured enzymatically. High-density lipoprotein cholesterol (HDL-C) and LDL-C were measured by a homogeneous direct method (Roche Diagnostics, Mannheim, Germany).

HOMA-Estimated Insulin Resistance Score {#S0002-S2005}
---------------------------------------

Fasting serum insulin and serum glucose test results were used to calculate the HOMA-IR used to assess insulin resistance score using the following formula HOMA-IR= (glucose in mmol/L × insulin in mIU/mL)/22.5.[@CIT0028] Those with HOMA-IR \>1.8 were considered to be insulin resistant.[@CIT0029],[@CIT0030]

ELISA Analysis {#S0002-S2006}
--------------

Levels of IL-6, IL-8, and soluble TM in serum samples were measured using ELISA by applying a biotin-streptavidin-peroxidase detection system with the respective Abcam kits (IL-6, Cat \# ab46042; IL-8, Cat \# ab46032; and CD141, Cat \# ab46508 Cambridge, MA, USA) according to the manufacturer's instructions. Each sample was assayed in duplicate and values were expressed as the mean of 2 measures per sample.

Statistical Analysis {#S0002-S2007}
--------------------

### Univariate Analysis {#S0002-S2007-S3001}

Participants' independent variables consisted of demographic variables, ethnic subgroups, educational level, BMI, waist circumference, smoking status, serum 25(OH)D status, and lipid profile. In [Table 1](#T0001){ref-type="table"} and [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=245742.docx)]{.ul}, continuous variables with normal distribution were presented as mean and standard deviation (SD); non-normal variables were reported as median and interquartile range (IQR). Categorical variables were reported as counts and percentages. For two-way analysis, variables were compared across groups using *χ*^2^ test for categorical data and Student's *t*-test or Mann--Whitey *U*-test for continuous data depending on skewness of the data.Table 1Characteristics of Participants Stratified by Insulin-Resistant and Insulin-Sensitive StatusCharacteristicsInsulin-Resistant n=2760Insulin-Sensitive n=1354*P*-valueAge (SD), years40 (12)38 (12)\<0.001Sex (%) Male1848 (74)862 (70)0.025 Female641 (26)357 (30)Race/Ethnicity Arabs1052 (45)598 (53)\<0.001 Asian1221 (53)503 (44) Others^a^49 (2)35 (3)Education Less than high school406 (16)188 (15)0.015 High school diploma1117 (45)588 (48) University bachelor's degree748 (30)372 (31) Postgraduate degree201 (8)66 (5)BMI Categories Underweight18 (1)40 (4)\<0.001 Normal562 (25)525 (48) Overweight1020 (45)388 (35) Obese683 (30)149 (13)Waist Circumference Abdominally obese1012 (41)292 (24)\<0.001 Non-abdominally obese1447 (59)914 (76)Average level of physical activity per day1.01 ± 2.01.15 ± 2.10.067Smoking Status Current smoker463 (19)222 (18)0.927 Former smoker106 (4)51 (4) Never smoker1874 (77)929 (77)Serum 25(OH)D, median (IQR), ng/mL28.50 (18.5)31.20 (21.4)\<0.001Serum D \[25(OH)D\], Status (%) High concentration (\>50 ng/mL)283 (11)178 (16)\<0.001 Sufficiency (20--50 ng/mL)1751 (67)751 (66) Deficiency (\<20 ng/mL)588 (22)208 (18)Lipid Profile HDL (\<1.55 mmol/L)2531 (92)970 (72)\<0.001 LDL (\>2.59 mmol/L)2242 (81)888 (66)\<0.001 TG (\>2.3 mmol/L)614 (22)94 (7)\<0.001 Total cholesterol (\>6.2 mmol/L)402 (15)114 (8)\<0.001[^1]

Multivariate Analysis and Model Development {#S0002-S2008}
-------------------------------------------

The first aim of the study was to identify the association between serum 25(OH)D level and risk of dyslipidemia using a logistic regression model, adjusted for age, sex, ethnicity, educational level, BMI, and smoking status. These cofounding variables were selected for logistic regression model according to their clinical[@CIT0031] and statistical significance.[@CIT0032] To avoid any strong correlation among the variables in the model, they were evaluated for multicollinearity by measuring the variance inflation factors and magnitude of standard errors.

Comparison of Serum Levels of IL-6, IL-8, and Soluble TM in 25(OH)D- Deficient Compared to 25(OH)D-Sufficient Insulin-Resistant Individuals {#S0002-S2009}
-------------------------------------------------------------------------------------------------------------------------------------------

The second aim of this study was to compare the median IL-6, IL-8, and soluble TM serum levels between 25(OH)D﻿-deficient and 25(OH)D﻿-sufficient insulin-resistant individuals. Mann--Whitey *U*-test was used for the two-way analysis between these variables.

All analysis was two-sided, with a *P*-value of \<0.05 considered statistically significant. The analysis was performed using SPSS Version 26 (IBM Corporation, Chicago, USA) and Graphpad Prism 7 (GraphPad Software Inc., San Diego, USA).

Results {#S0003}
=======

[Table 1](#T0001){ref-type="table"} demonstrates the characteristics of the participants from the UAEDIAB study (n=4114) categorized by insulin resistance status. Insulin-resistant individuals were more obese (30% vs. 13%, P\<0.001) and had higher fasting serum lipid-profiles (HDL-C dyslipidemia \[92% vs. 72%, P\<0.001\]; LDL-C dyslipidemia \[81% vs. 66%, P\<0.001\]; TG dyslipidemia \[22% vs. 7%, P\<0.001\]; TC dyslipidemia \[15% vs. 8%, P\<0.001\]) compared with insulin-sensitive individuals. The proportion of 25(OH)D deficiency was higher for insulin-resistant individuals as well (22% vs. 18%, P\<0.001). Participants\' characteristics according to serum 25(OH)D status categories are shown in [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=245742.docx)]{.ul}.

Association of 25(OH)D Deficiency with HDL-C Dyslipidemia in Insulin-Resistant Individuals {#S0003-S2001}
------------------------------------------------------------------------------------------

Results from the multiple logistic regression models adjusted for age, sex, ethnicity, educational level, BMI, and smoking status are presented in [Table 2](#T0002){ref-type="table"}. Insulin-resistant individuals with deficient 25(OH)D had a significantly increased risk of HDL-C dyslipidemia compared with the reference group (OR 2.09 \[95% CI, 1.18-3.39\]; P=0.009), but there was no significant association between other dyslipidemias and 25(OH)D deficiency in insulin-resistant subjects.Table 2Odds Ratios (ORs) for the Association Between Serum 25(OH)D Levels and Insulin-Resistance Status Stratified by Lipid-ProfileLipid Profile25(OH)D Status^a^Insulin-SensitiveInsulin-ResistantOR (95% CI)*P-value*OR (95% CI)*P*-valueHDL (\<1.55 mmol/L)Sufficient11Deficient1.00 (0.57--1.74)0.9982.09 (1.18--3.39)0.009LDL (\>2.59 mmol/L)Sufficient11Deficient1.27 (0.75--2.13)0.3601.09 (0.79--1.52)0.935TG (\>2.3 mmol/L)Sufficient11Deficient1.53 (0.74--3.15)0.2421.24 (0.94--1.64)0.130Total cholesterol (\>6.2 mmol/L)Sufficient11Deficient0.93 (0.46--1.87)0.8441.35 (0.99--1.84)0.055[^2]

Serum 25(OH)D-Deficient Insulin-Resistant Individuals Had Higher Serum IL-6, IL-8, and Soluble TM Levels {#S0003-S2002}
--------------------------------------------------------------------------------------------------------

We found that insulin-resistant individuals who had 25(OH)D deficiency had higher serum IL-6, IL-8, and soluble TM levels compared to those with 25(OH)D sufficiency and normal-lipid profiles (median, IL-6 pg/mL 0.82 vs 1.71, *P*=0.001; median, IL-8 pg/mL 51.31 vs 145.6, *P*=0.003; and median, solubleTM ng/mL 5.19 vs 7.38, *P*\<0.0001; in serum 25(OH)D﻿-sufficient vs serum 25(OH)D﻿-deficient groups, respectively) ([Figure 2A](#F0002){ref-type="fig"}--[C](#F0002){ref-type="fig"}). Also, there was an inverse correlation between serum 25(OH)D and solubleTM levels in insulin-resistant individuals (*r*=−0.342, *P*=0.010) ([[Supplementary Figure 1](https://www.dovepress.com/get_supplementary_file.php?f=245742.docx)]{.ul}).Figure 2Elevated serum of IL-6, IL-8, and soluble TM levels in 25(OH)D-deficient insulin-resistant individuals. Representative data showing an increase in the serum levels of IL-6 (**A**), IL-8 (**B**), and soluble TM (**C**) in 25(OH)D-deficient compared to 25(OH)D-sufficient insulin-resistant individuals. The cytokine levels were estimated using human ELISA assays. \*\*P\<0.01, \*\*\*\*P\<0.0001.

Discussion {#S0004}
==========

In this study, by recruiting 4114 individuals with different ethnicities living across UAE, we were able to determine that low serum levels of HDL-C is the characteristic dyslipidemia seen in 25(OH) D-deficient insulin-resistant subjects. Moreover, we found increased levels of circulating pro-inflammatory markers such as IL-6 and IL-8, and endothelial damage marker,[@CIT0033] thrombomodulin, in 25(OH)D﻿-deficient insulin-resistant individuals ([Figure 1](#F0001){ref-type="fig"}). Since numerous studies have identified HDL-C dyslipidemia as an independent predictor of CV events[@CIT0034]--[@CIT0037], our results imply that links between serum level of 25(OH)D lower than 20 ng/mL and CV events might be through HDL-C and serum levels of IL-6, IL-8, and soluble TM in insulin-resistant individuals who have proven to be at significant increased CV disease risk.[@CIT0038]

Although it is a general agreement that high serum 25(OH)D levels are associated with a favorable serum lipid profile; it is highly controversial which lipids may be affected by increased serum 25(OH)D levels. The association between deficient 25(OH)D and HDL-C dyslipidemia found in this study is consistent with prior studies by Faridi et al[@CIT0010] and Lupton et al.[@CIT0011] Ponda et al[@CIT0013] that aimed to determine the association between serum 25(OH)D and lipid profile reported that raising serum 25(OH)D levels from 20 to 30 ng/mL in 6260 subjects was associated with a mean increase in TC and HDL-C, but, nonsignificant changes in LDL-C and TG. By taking the insulin variable in consideration, and adjusting for demographic, lifestyle, and use of lipid-lowering medications, our study was able to show that low serum 25(OH)D levels is associated with HDL-C dyslipidemia in insulin-resistant individuals.

Notably, in this study, we have seen that in our multi-ethnic cohort, insulin-resistant state was associated with unfavorable lipid-profiles, particularly increased LDL-C, TC, and TG and decreased HDL-C as compared with insulin-sensitive state. Previous studies have mainly linked TG and HDL-C with insulin-resistant state, or used the TG-HDL-C ratio as a surrogate of insulin resistance;[@CIT0029],[@CIT0030] However, the relation between the TG-HDL-C ratio with insulin-resistant state might differ by ethnicity as there is a report that the TG-HDL-C ratio are not a marker of insulin resistance in black African-Americans population.[@CIT0039]

Association of serum 25(OH)D deficiency with circulating pro-inflammatory cytokines such as IL-6[@CIT0040],[@CIT0041] and IL-8[@CIT0042] is in line with numerous reports[@CIT0043] but our study is novel in linking low serum 25(OH)D to higher circulatory IL-6 and IL-8 in insulin-resistant individuals, and to elevated serum TM levels, in particular. Thrombomodulin, is a glycoprotein that is found both membrane-bound in the vascular endothelium and in a soluble form in the plasma. The membrane-bound TM is dissociated from the endothelium during disorders involving vascular damage, such as various infections, sepsis, and inflammation, presumably cleaved from endothelial cells by neutrophil-delivered enzymes, and becomes soluble in systemic circulation.[@CIT0044] Taken together, soluble TM is considered as a marker of endothelial damage and has been reported as such in various studies.[@CIT0033],[@CIT0045]

Moreover, the role of TM in inflammation has also been reported and thrombomodulin expression in monocytes triggers lipopolysaccharide-induced inflammatory response,[@CIT0046] resulting in higher circulatory IL-6. Another report showed that the vascular endothelial expression of vitamin D receptor and 1-alpha hydroxylase, the 25(OH)D to 1,25-dihydroxyvitamin D converting enzyme, was lower in 25(OH)D﻿-deficient versus -sufficient middle-aged adults, suggesting that endothelial damage can mediate nuclear-κB signaling, resulting in increased synthesis of pro-inflammatory cytokine IL-6 in vitamin D﻿-deficient versus sufficient subject.[@CIT0047] Furthermore, another study also related the anti-inflammatory effect of vitamin D to downregulating NF-κB signaling.[@CIT0048] In our study, compared with sufficient 25(OH)D individuals, deficient 25(OH)D had higher serum levels of downstream nuclear-κB related inflammatory markers such as IL-6 and IL-8. Although soluble TM is not included in the subsets of NF-κB target genes, its endothelial expression has been reported to be mediated through TNF-alpha signaling that is part of NF-κB pathway.[@CIT0049] However, the exact molecular mechanisms underlying the protective effect of vitamin D on reducing inflammation-induced vascular endothelial damage and its relation to serum levels of soluble TM is not well elucidated and requires further research.

Moreover, in this study insulin-resistant individuals had lower median serum 25(OH)D levels as compared to insulin-sensitive individuals. Low 25(OH)D serum levels in these individuals were also associated with HDL-C dyslipidemia, increased serum levels of inflammatory markers, including IL-6 and IL-8, and enhanced levels of soluble TM, as a marker of endothelial damage. Given that insulin resistance is proven to be at risk to develop CV disease,[@CIT0038] vitamin D supplementation could reduce endothelial dysfunction leading to CVD in insulin-resistant individuals who have proven to be at significant increased CVD risk.[@CIT0038]

There are a few limitations in our study that must be acknowledged. Firstly, although our study features a large, nationally representative sample that improves the generalizability of our results, a limitation is its cross-sectional nature. Information and blood samples were taken from study participants at the same point in time and longitudinal follow-up data is not available. Secondly, we were unable to assess the longitudinal effects of changes in serum 25(OH)D and its impact on serum lipid profiles. However, in line with our result that HDL-C dyslipidemia is associated with serum 25(OH)D deficiency, a cohort study with longitudinal follow-up design has shown that raising serum 25(OH)D levels from \<20 ng/mL to \>30 ng/mL was associated with a mean increase in HDL-C levels but nonsignificant changes in serum LDL-C and TGs levels.[@CIT0013] Thirdly, in this study, the inverse relationship between elevated serum TM levels, marker of inflammation-induced endothelial damage,[@CIT0033] and low serum 25(OH)D (\<20 ng/mL) in insulin-resistant individuals was based on small sample sizes. Hence, we recommend future studies to evaluate its validity and applicability in a larger cohort.

In conclusion, our study has found that serum levels of 25(OH)D lower than 20 ng/mL is associated with HDL-C dyslipidemia in insulin-resistant individuals with increased serum levels of inflammatory markers, including IL-6 and IL-8, and enhanced levels of soluble TM, as a marker of endothelial damage.
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[^1]: **Notes:** ^a^Others were defined as Westerners and Africans. Statistical significance: *P* ≤ 0.05.

[^2]: **Notes:** ^a^Adjusted for age, sex, ethnicity, educational level, BMI, and smoking status. Statistical significance: *P* ≤ 0.05.
